Cart
sales@molnova.com
Tyk2-IN-30
CAS No. 1334407-95-2
Tyk2-IN-30( —— )
Catalog No. M11333 CAS No. 1334407-95-2
TYK2-IN-30 is a potent, selective and orally active Tyk2 inhibitor with Ki of 0.7 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTyk2-IN-30
-
NoteResearch use only, not for human use.
-
Brief DescriptionTYK2-IN-30 is a potent, selective and orally active Tyk2 inhibitor with Ki of 0.7 nM.
-
DescriptionTYK2-IN-30 is a potent, selective and orally active Tyk2 inhibitor with Ki of 0.7 nM, exhibits excellent selectivity (35-fold for JAK1 and 83-fold for JAK3); potently inhibits IL-23 pathway in cells with EC50 of 66 nM, and has good pharmacokinetic properties; demonstrates dose-dependent reduction of IL-17 production in a PK/PD model as well as in an imiquimod-induced psoriasis model.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1334407-95-2
-
Formula Weight396.235
-
Molecular FormulaC18H11Cl2N7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name3,5-dichloro-4-(4-((6-methylpyrimidin-4-yl)amino)-3H-imidazo[4,5-c]pyridin-2-yl)benzonitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PF-06651600
PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical
-
Atiprimod
Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways.
-
CEP-33779
CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
